Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterNo recent work listed

David Lawrence Bajor

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2702-5008; OpenAlex author ID A5051445471, A5078692994. Sources: ClinicalTrials.gov.

Their work

Papers
12 (first author 1, last author 0)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
0
Collaborators
46
Papers, trials and grants by year

2013: 2 papers, 1 trial · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 trial · 2019: none · 2020: 2 papers · 2021: 2 papers · 2022: 3 papers, 1 trial · 2023: 2 papers

Papers 12

  1. Disparities in guideline-compliant care for patients with pancreatic ductal adenocarcinoma at minority-versus non-minority-serving hospitals. Co-author DOI 10.1016/j.hpb.2023.07.903↗
  2. Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. Co-author DOI 10.1056/nejmoa2208470↗
  3. Combined multiagent chemotherapy and radiotherapy is associated with prolonged overall survival in patients with non-operatively managed stage II-III pancreati… Co-author DOI 10.1016/j.hpb.2021.08.938↗
  4. Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2022.07.007↗
  5. A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. Co-author DOI 10.1016/j.surg.2021.10.023↗
  6. Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-21-1047↗
  7. Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagen… Co-author DOI 10.1177/00031348211038581↗
  8. Neoadjuvant chemotherapy is associated with improved survival in patients with left-sided pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.26196↗
  9. A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? Co-author DOI 10.18632/oncotarget.27727↗
  10. Lack of immunoediting in murine pancreatic cancer reversed with neoantigen. Co-author DOI 10.1172/jci.insight.88328↗
  11. CD40 immunotherapy for pancreatic cancer. First author DOI 10.1007/s00262-013-1427-5↗
  12. Cracking the stone: combination vaccination and CTLA-4 blockade in pancreatic cancer. Co-author DOI 10.1097/cji.0b013e31829fb7c8↗

Trials 3

  1. Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma Principal investigator NCT05209074↗
  2. CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer Principal investigator NCT03699319↗
  3. Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer Principal investigator NCT01666730↗

Closest collaborators

The 25 strongest of 46 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. John Brian Ammori · 7 shared papers, 2020–2023 · strength 0.95
  2. Lee Mayer Ocuin · 7 shared papers, 2020–2023 · strength 0.95
  3. Jeffrey M. Hardacre · 7 shared papers, 2020–2023 · strength 0.95
  4. Jordan Michael Winter · 7 shared papers, 2020–2023 · strength 0.95
  5. Jonathan J. Hue · 5 shared papers, 2020–2022 · strength 0.66
  6. Luke Daniel Rothermel · 5 shared papers, 2020–2022 · strength 0.65
  7. Mohamedraed Elshami · 3 shared papers, 2022–2023 · strength 0.44
  8. Richard S. Hoehn · 2 shared papers, 2022–2023 · strength 0.31
  9. Robert H. Vonderheide · 4 shared papers, 2013–2021 · strength 0.26
  10. Jennifer Anne Dorth · 2 shared papers, 2021–2022 · strength 0.26
  11. Kavin Sugumar · 2 shared papers, 2021–2022 · strength 0.26
  12. Erryk Katayama · 2 shared papers, 2020–2022 · strength 0.26
  13. Sakti Chakrabarti · 1 shared paper, 2023 · strength 0.17
  14. Amit Mahipal · 1 shared paper, 2023 · strength 0.17
  15. Katelyn T. Byrne · 2 shared papers, 2016–2021 · strength 0.14
  16. Hanna H. Kakish · 1 shared paper, 2022 · strength 0.14
  17. Laëtitia Dahan · 1 shared paper, 2023 · strength 0.14
  18. John H. Strickler · 1 shared paper, 2023 · strength 0.14
  19. Charlotte Lemech · 1 shared paper, 2023 · strength 0.14
  20. Antoine Hollebecque · 1 shared paper, 2023 · strength 0.14
  21. Andrew L. Coveler · 1 shared paper, 2023 · strength 0.14
  22. Yu Sunakawa · 1 shared paper, 2023 · strength 0.14
  23. Thomas J. George · 1 shared paper, 2023 · strength 0.14
  24. Rona D. Yaeger · 1 shared paper, 2023 · strength 0.14
  25. David S. Hong · 1 shared paper, 2023 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.